Rani Therapeutics Holdings (RANI) Operating Income (2020 - 2026)

Rani Therapeutics Holdings' Operating Income history runs 7 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• On a quarterly basis, Operating Income rose 30.58% year-over-year to -$8.3 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 32.48% increase from a year earlier, with the FY2025 full-year figure at -$38.3 million, up 28.14% from the prior year.
• Operating Income grew to -$8.3 million in Q1 2026 per RANI's latest filing, from -$8.5 million in the prior quarter.
• Across five years, Operating Income topped out at -$7.3 million in Q3 2025 and bottomed at -$18.3 million in Q2 2023.
• The 5-year median for Operating Income is -$13.8 million (2022), against an average of -$13.5 million.
• Across the five-year window, Operating Income sank 201.39% in 2022 and surged 42.94% in 2025, its largest moves.
• Year by year, Operating Income stood at -$17.5 million in 2022, then gained by 23.16% to -$13.4 million in 2023, then slipped by 11.34% to -$15.0 million in 2024, then surged by 42.94% to -$8.5 million in 2025, then rose by 2.3% to -$8.3 million in 2026.
• Per Business Quant, the three latest RANI Operating Income figures stand at -$8.3 million (Q1 2026), -$8.5 million (Q4 2025), and -$7.3 million (Q3 2025).